This content is machine translated Cutaneous T-cell lymphoma (CTCL) First targeted antibody approved for CTCL patients with MF or SS The approval of the anti-CCR4 antibody mogamulizumab provides patients with cutaneous T-cell lymphoma (CTCL) of the mycosis fungoides (MF) and Sézary syndrome (SS) subtypes with an effective non-chemotherapeutic intervention for…
